Ionis Pharmaceuticals (IONS) Stock: Here’s What You Need To Know

Ionis Pharmaceuticals (NASDAQ:IONS) After the market closed on December 23, Ionis had announced that it had received FDA approval, together with Biogen, for its Spinal Muscular Atrophy drug. This drug, known as Spinraza, was developed by both companies to treat patients with Spinal Muscular Atrophy (SMA), a rare-genetic disorder. This was a huge surprise because … Read more

Biotech Stock News (AVXL) (BIIB) (LLY) (SPHS) (KBIO)

Anavex Life Sciences (NASDAQ:AVXL) On November 9, 2015 Anavex reported positive phase 2a results for the trial treating patients with Alzheimer’s. This trial tested two clinical endpoints. The first clinical endpoint was testing for safety as it is customary with all phase 2a trials. The second endpoint was looking for preliminary clinical efficacy. In terms … Read more

Biotech Stock News (AMGN) (RGLS) (BIIB) (RVNC) (AGN)

Amgen, Inc. (NASDAQ:AMGN) On October 28, 2015 Amgen had announced that it had received FDA approval for its skin cancer drug known as IMLYGIC. This drug is an injection type drug that helps boost the immune system to fight off and kill cancerous skin cells. This therapy only treats Melanoma — skin cancer– but does … Read more

Biotech Stock News (BIIB) (LLY) (AVXL) (ITEK) (XOMA)

Biogen (NASDAQ:BIIB) On July 22, 2015 shares of Biogen fell about 4% after reporting mixed results for its Alzheimer’s drug known as aducanumab. This phase 1b trial was known as the “PRIME” trial and patients were randomized into two different dosing groups. One group of patients either took 1 mg, 3 mg , 6 mg … Read more

Biogen (BIIB) Declines On Earnings | Will It Bounce Back?

Biogen Inc (NASDAQ: BIIB) Biogen is down in a big way today after reporting earnings for the second quarter. Overall, earnings were positive, but an update to guidance obviously rubbed investors the wrong way. Today, we’ll talk about the Q2 earnings from BIIB, the change in guidance, how investors reacted, and what we can expect … Read more

Biotech Stock News (SRPT) (JUNO) (CELG) (AGTC) (VRTX)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday June 29, 2015 Sarepta had announced that it had completed¬†its rolling submission of its New Drug Application — NDA — to the FDA. A rolling submission is an FDA policy whereby biotech companies can submit their marketing approval application in small parts on a rolling basis instead of doing it … Read more

Biotech Stock News (RXII)(REGN)(SNY)(ESPR)(ISIS)(BIIB)

Rxi Pharmaceuticals (NASDAQ:RXII) On June 9, 2015 shares of Rxi Pharmaceuticals went up 6% after the company reported that two new key patents were given to the company for use with their self-delivering sd-rxRNA technology platform. The new patents establish a few new details that enhance upon the company’s prospects: First the new patent is … Read more

Has Biogen (BIIB) Reached The Floor? Uptrends To Come!

Biogen Inc (NASDAQ: BIIB) Biogen stock has had a rough time in the market recently. After producing an earnings report that showed big misses on both top line revenue and earnings per share, the company’s stock started to fall dramatically; losing more nearly $50 per share over the past 4 days. However, it’s my opinion … Read more

Biogen (BIIB) Stock Continues To Decline On Missed Earnings

Biogen Inc (NASDAQ: BIIB) Biogen is a massive biotech company that’s been dealt a heavy hand in the market recently. After missing earnings expectations last week, the stock started to free fall; leading to a big question. Will Biogen continue on the free fall pattern, or will it bounce back. Here’s a glimpse at earnings, … Read more